PSNL News and Press, Personalis Inc. From 12/04/23

Workforce restructuring and recent commercial collaboration help position company for long-term success Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staf...

2023-12-01 17:09:11 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis: Collaborations Should Ignite Growth Narrative Personalis to issue 9.2M shares as Tempus joins hands for cancer test Personalis GAAP EPS of -$0.60 mi...

2023-11-29 14:41:57 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis: Collaborations Should Ignite Growth Narrative Personalis GAAP EPS of -$0.60 misses by $0.08, revenue of $18.2M beats by $1.22M Personalis Q3 2023 Ea...

Exclusive arrangement will expand market access to Personalis’ ultra-sensitive MRD test Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc. , a leader in artificial intelligence and precision medicine, today announ...

2023-11-07 23:04:10 ET Personalis, Inc. (PSNL) Q3 2023 Earnings Conference Call November 07, 2023, 05:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Re...

2023-11-07 16:04:47 ET More on Personalis Personalis: Collaborations Should Ignite Growth Narrative Personalis Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Personalis Historical earnings data for Personalis For further details see: ...

Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting NeXT Personal’s market leading sensitivity for cancer recurrence detection Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision on...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Personalis Inc. (PSNL) is expected to report $-0.54 for Q3 2023

NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time improvements in detecting cancer Personalis, Inc . (Nasdaq: PSNL), a leader i...